Drugs

FDA Eyes Reviewer Bonuses to Speed Reviews

FDA is preparing to roll out a new bonus program that will reward drug and biologic reviewers for completing high-quality drug reviews ahead of schedule, in a bid to accelerate regulatory decisions, according to a Bloomberg news report. According to an FDA official, the incentive program will provide quarterly bonuses of roughly several thousand dollars to scientific reviewers whose work is both timely and judged to be of high quality. The exact bonus amounts are still being finalized, and the agency plans to brief employees on the program at an internal meeting this week.

The bonuses will apply to reviewers in CDER and CBER and is scheduled to begin 4/1. The bonus initiative comes as the FDA is undergoing a hiring spree to add more than 1,000 additional scientists as part of a broader effort to speed drug evaluations. Leadership is positioning the bonuses as a tool to improve review timeliness while reinforcing expectations around scientific rigor and documentation quality, according to Bloomberg.

For drug sponsors, the move signals intensified pressure inside the agency to meet or beat user‑fee goal dates, potentially reducing review-cycle slippage on original NDAs/BLAs and supplements. However, the emphasis on “high‑quality” work suggests internal controls and supervisory review will be critical to ensure faster timelines do not undercut the robustness of safety and efficacy assessments.

If implemented as described, the program could modestly shorten effective review times in cases where scientific questions are straightforward and data packages are complete at submission. Sponsors may face more intensive information requests earlier in the review clock as staff aim to keep files on track for early completion.

Patient and public‑health advocates are likely to scrutinize the initiative for any sign that financial incentives could bias reviewers toward quicker approvals or reduced scrutiny. In parallel, industry groups may welcome the effort as a signal that the agency is investing in reviewer retention and performance at a time of rising submission volumes and increasingly complex products.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome